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Abstract- Mitoxantrone (MX) is an important antineoplastic drug used for treatment of 
different types of cancer with lower side effects. The purpose of this study is to shade more 
light on the mechanism of interaction between MX and biological molecules. This study 
would result in drug design and development.  Molecular structure was computed at the 
B3LYP/6-31+G(d) level. All possible intramolecular hydrogen bonding interactions were 
considered and calculated at the same level. Five conformers of MX were located and 
computed to lie in the energy range 0.000-48.495 kcal/mol. Molecular reactivity of MX 
towards biological systems was explored using condensed molecular descriptors, Fukui 
functions of electrophilic, nucleophilic and free radical attack. Molecular docking studies 
for the inhibition of CDK2 and DNA binding were carried out to explore the anticancer 
potency of MX. The role of charge transfer binding in the interaction of MX with biological 
molecules was investigated via studying the ability of MX to act as a charge transfer 
acceptor with known donors using NMR spectroscopy. Charge transfer complex formation 
was confirmed by proton chemical shift and stability constants were measured from the 
NMR chemical shift data. Stability constants of MX with donors, phenylene diamine, 
hexamethyl benzene and pyrene are 4.178, 2.527 and 1.240 M-1 respectively. 
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Mitoxantrone is a symmetric drug composed of tricyclic planar chromophore and two basic 
side chains. It is an important antineoplastic drug belonging to the anthracycline group. 
Mitoxantrone is being used for treatment of different types of cancer including myeloid 
leukemia, breast cancer, lung cancer, and prostate cancer [1–6]. Mitoxantrone is considered 
a chemotherapeutic drug possessing the potent cytotoxicity of the anthracycline drug 
family with lower side effects towards cardiotoxicity [5–8]. Anthracycline drugs are known 
to exert their cytotoxic effects through interaction with DNA resulting in modification of 
its structure hence inhibition of its replication [9]. Mitoxantrone is known inhibitor to 
topoisomerase II [10]. Mitoxantrone shows covalent and noncovalent interactions with 
many biological macromolecules [9]. However, to the best of our knowledge, there is no 
reported work on the forces of interaction of this important drug with biological systems 
especially charge transfer forces. In this work, the importance of such force will be 
investigated through studying the interaction of MX with known charge transfer agents 
especially, charge transfer donors. 
Although many experimental chemical and physical phenomena of MX are studied [11-
16] only few quantum chemical calculations are reported [17-23]. There is a lack of 
theoretical studies on MX. In the present work, charge transfer formation of MX with 
known charge transfer donors were studied to determine the possibility of charge transfer 
binding of MX/macromolecules interaction. In addition to that computational geometrical 
and electronic properties of MX are investigated. This paper is organized as follows: 
Section 2 gives details of the computational methods. Section 3 presents the results and 
discussion and is divided into three subsections. This is followed by Section 4, which 
summarizes main conclusions. 
 
COMPUTATIONAL DETAILS 
All computations were done using G16W suit of programs [24]. Molecular geometry of 
MX was optimized in the gas phase at DFT B3LYP/6-31+G(d,p) level of theory. Different 
conformers considering possible intramolecular hydrogen bonding of MX were computed. 
A frequency job was performed following each geometry optimization step to confirm a 
minimum energy structure and to correct energy for zero-point vibrational energy. Fukui 
functions were calculated using DMol3 module [25,26] employing B3LYP/DND method 






Mitoxantrone was supplied from Aldrich with a purity limit of 97% and recrystallised twice 
from dichloromethane. p-Phenylenediamine, hexamethylbenzene and pyrene 
(spectroscopic grade (+99%)) supplied from Aldrich were used without further 
purification.  
 
NMR Measurements, General Method 
Nuclear magnetic resonance spectra were recorded in chloroform-d using a BRUKER 
AC250 machine at 30 oC. NMR data were employed to calculate the equilibrium constant 
of the MX charge transfer complexes according to the relation described below [28,29]. 
Stock solutions of MX and other charge transfer donors in CDCl3 were prepared. For NMR 
scan a series of sample solutions were produced by accurate dilution from the stock 
solutions keeping constant MX concentration and varying the concentration of the other 
CT agent. The chemical shift of the MX bands was measured with reference to the internal 
standard, TMS. To estimate the uncertainty in the experimental results, all the 1H NMR 





RESULTS AND DISCUSSION 
 
Potential energy surface of molecular conformation based on possibility of intra molecular 
hydrogen bonding formation, was studied. Five minimum energy conformers, Conf-1, 
Conf-2, Conf-3 Conf-4 and Conf-5, of MX were computed and displayed in Fig. 1. Conf-
1 allows four intra-molecular hydrogen bonds while Conf-2 allows three intra-molecular 
hydrogen bonds and Conf-3 and Conf-4 allow two and one intra molecular hydrogen 
bonds, respectively, while Conf-5 has no hydrogen bonds (see Fig. 1). The relative total 
energies differences are shown in Fig. 1. Conf-1 with four intra molecular hydrogen bonds 
is the most stable structure separating from Conf-5, with no hydrogen bond, by 48.495 
kcal/mol. Conf-2 with three hydrogen bonds is the next stable structure with energy 
difference 14.135 kcal/mol and Conf-3, with two hydrogen bonds, is separating from Conf-
1 by 29.017 kcal/mol. Conf-4 with only one hydrogen bond is separated from the most 
stable structure, global minimum, by 38.066 kcal/mol. The least stable conformer with no 
intra molecular hydrogen bonds, Conf-5, has a relative energy of 48.495 kcal/mol. One can 
conclude that each intramolecular hydrogen bond contributes a mean value of 12.124 
kcal/mol to the stabilization of molecular MX.  
Optimized geometry of MX conformers is shown in Fig. 1. All optimized structures, 
energies and geometries of MX, Conf-1-5, are represented in Fig. 1S-5S in the 




Conf-1, DE=0.000 kcal/mol 
 
Conf-2, DE=14.135 kcal/mol 
 
Conf-3, DE=29.019 kcal/mol 
 
Conf-4, DE=38.066 kcal/mol 
 
Conf-5, DE=48.495 kcal/mol 
Fig. 1. Optimized structure of MX conformers showing atomic numeration, H-bonding and relative 
energy. 
Natural atomic charges of MX were computed and displayed in Fig. 2 and additionally 
presented in Table 1S in the Supplementary Materials. Charges are distributed on the 
structure atoms and accumulation of charge cannot be detected on any part of the molecule. 
All H's are positively charged (0.2-0.4) and H's bonded oxygen (≈ 0.5). Hydrogens 
involved in intramolecular hydrogen bonding have extra positive charge (≈ 0.043 for O-
H…O and ≈ 0.077 for N-H…O) more than those not engaged in hydrogen bonding of the 
side chain. All oxygen and nitrogen atoms are negatively charged (O: ≈ 0.7-0.8, N: ≈ 0.6-
0.7). Carbon atoms have negative charge (≈ 0.1-0.3) except ring carbon atoms attached to 
oxygen and nitrogen which are positively charged (≈ 0.2-0.5). Another effective way for 
obtaining information about the distribution of the active sites of a molecule is to calculate 
its molecular electrostatic potential map. The MEP surface of Mitoxantrone was calculated 
and displayed in Fig. 3. Negative potential centers are shown on oxygen atoms as expected. 
Highly positive centers are presented on hydrogen atoms of the hydroxyl groups of the side 
chains.  
One of the most important molecular features of molecules is molecular orbital and its 
property like atomic contribution coefficients and energy. Frontier orbitals such as highest 
occupied molecular orbital, HOMO and lowest unoccupied molecular orbital, LUMO are 
the most important. Molecular orbital surfaces of HOMO and LUMO are shown in Fig. 3. 
HOMO is delocalized mainly on the ring and oxygen and nitrogen atoms bonded to ring 
with highest density on carbons 1, 6, 7, 9, 11, 12, 13, 14. C2-C4, C2-C3, C4-C5, C6-C7, 
C8-C17 and C13-C14 bonds show anti-bonding nature where no electron projection at 
these regions. Side chains have no contribution to the HOMO. LUMO is being participated 
highly from C1, C8, C9, C3, C5, C13 and C14. It is clear from Fig. 3 that, the LUMO 
shows antibonding character over the C-H bonds and some C-C ring bonds. Side chains 
also have no contribution to the LUMO. In the ground state the frontier electron density is 
delocalized on the planar tri-cyclic ring and when some electrons excited to the LUMO the 
electron density will redistributed but still found on the anthraquinone ring. This implies 
that, the most reactive part of the MX is the planar ring system which accommodates the 
frontier orbitals as shown from Fig. 3. Since we are interested in studying the charge 
transfer properties of MX orbital surfaces of other significant molecular orbitals such as, 
HOMO-1, HOMO-2 and LUMO+1 also computed and displayed in Fig. 3. As could be 
expected, HOMO-1 is also located on the tricyclic ring but the HOMO-2 is contributed 
from one side chain. This suggests the importance of considering these orbitals, especially 










HOMO, -5.292 eV 
 
LUMO, -3.045 eV 
 
HOMO-1, -6.097 eV 
 
HOMO-2, -6.733 eV 
 
LUMO+1, -1.306 eV 
 
MEP 
Fig. 3. Important molecular orbitals surface with their energies and molecular 
electrostatic potential of MX. 
 
 
Fukui function gives the sensitivity of chemical potential of a system to an external 





Where        is the electron density. In order to describe the reactivity of an atom in a 
molecule, condensed Fukui functions (ƒk) that characterizes the atomic contribution in a 
molecule towards a certain reaction should be used. For an atom k in a molecule, the ƒk 
values are defined as 
 
                                                                              for nucleophilic attack            
                                                                              for electrophilic attack          
                                                                              for radical attack                                                             
 
 
We employed the above equations to calculate the value of the condensed Fukui function 
for every atom for electrophilic, nucleophilic and free radical attacks. By this way, the 
Fukui function can be used to determine the pin point distribution of the active sites on the 
MX drug. A qualitative approach of chemical reactivity was introduced Fukui [30] in the 
form of what we call Frontier Orbital Theory. This theory was demonstrated in the 
framework of DFT afterwards [31,32].  In a molecular system, the atomic site, which 
possesses highest condensed Fukui function, favors the higher reactivity. Table 1 shows 
the condensed Fukui functions as calculated based on Mullikin and Hirshfeld charges for 
MX. From the results of Table 1, the reactivity for the radical attack was found on 
N21=N23 > O45=O46 > C14 > C13 > O10=O18 > C8=C17 > C1=C9 > C12 > C3=C5. 
The most reactive site towards radical attack is nitrogen atoms attached to the ring.  For 
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nucleophilic attack, the most reactive sites are O18 (0.058) and O10 (0.057). The order of 
reactivity towards nucleophilic attack could be ranked as O18 > O10 > C14 > C13 > 
C8=C17 > C3=C5 > C5 > O45=O46 > N21=N23 > C1= C11 =C12. On the other hand, for 
electrophilic attack, the most reactive site is N21(0.066), N23(0.065), O45(0.051) and O46 
(0.050). The reactivity order towards electrophilic attack could be ranked as N21 > N23 > 
O45 > O46 > C7> C6=C8=C17 > C1 > C9 > C11 > C12=C14 > C13. Another conclusion 
could be withdrawn from the Table 1 is that MX is more likely to act as an electophile than 
being as a nucleophile. This finding is also, confirmed by the NMR charge transfer 
complexes interaction that shows MX acts as an electron acceptor with known charge 
transfer donors.  
 
  
Table 1. Condensed Fukui Functions (𝑓"#)  (𝑓"$) and (𝑓"%) indices of MX 
 
 Fukui Indices for radical 
attack 
𝒇𝒌𝟎 
Fukui Indices for nucleophilic 
attack 
𝒇𝒌$ 
Fukui Indices for electrophilic 
attack 
𝒇𝒌% 
 Mulliken Hirshfeld Mulliken Hirshfeld Mulliken Hirshfeld 
C (  1) 0.024 0.031 0.022 0.028 0.027 0.034 
C (  2) 0.007 0.010 0.006 0.012 0.007 0.009 
C (  3) 0.030 0.028 0.046 0.043 0.015 0.013 
C (  4) 0.007 0.010 0.006 0.012 0.008 0.009 
C (  5) 0.03 0.028 0.046 0.043 0.015 0.012 
C (  6) 0.018 0.023 0.006 0.011 0.030 0.035 
C (  7) 0.018 0.024 0.006 0.011 0.030 0.036 
C (  8) 0.027 0.040 0.032 0.046 0.022 0.035 
C (  9) 0.024 0.031 0.022 0.028 0.026 0.033 
O ( 10) 0.040 0.041 0.056 0.057 0.023 0.025 
C ( 11) 0.021 0.030 0.022 0.028 0.020 0.032 
C ( 12) 0.021 0.029 0.021 0.028 0.020 0.031 
C ( 13) 0.031 0.042 0.042 0.054 0.020 0.030 
C ( 14) 0.031 0.043 0.042 0.055 0.021 0.031 
H ( 15) 0.044 0.023 0.047 0.026 0.040 0.020 
H ( 16) 0.043 0.023 0.047 0.026 0.040 0.020 
C ( 17) 0.026 0.040 0.032 0.046 0.021 0.035 
O ( 18) 0.04 0.041 0.056 0.058 0.024 0.025 
H ( 19) 0.045 0.024 0.047 0.026 0.042 0.022 
H ( 20) 0.045 0.024 0.048 0.026 0.042 0.022 
N ( 21) 0.049 0.049 0.03 0.032 0.068 0.066 
H ( 22) 0.018 0.015 0.015 0.012 0.022 0.019 
N ( 23) 0.049 0.049 0.03 0.032 0.068 0.065 
H ( 24) 0.019 0.016 0.016 0.012 0.022 0.019 
C ( 25) 0.025 0.008 0.022 0.006 0.027 0.011 
C ( 26) 0.003 0.002 0.002 0.002 0.004 0.002 
H ( 27) 0.029 0.015 0.024 0.012 0.033 0.018 
H ( 28) 0.028 0.015 0.023 0.012 0.032 0.017 
H ( 29) 0.008 0.003 0.007 0.002 0.01 0.004 
H ( 30) 0.008 0.003 0.007 0.003 0.01 0.004 
N ( 31) 0.002 0.005 0.001 0.004 0.002 0.005 
C ( 32) 0.009 0.003 0.008 0.002 -0.01 0.003 
H ( 33) 0.001 0.001 0.001 0.001 0.002 0.001 
H ( 34) 0.013 0.006 0.012 0.005 0.014 0.006 
C ( 35) 0.021 0.008 0.019 0.006 0.023 0.010 
H ( 36) 0.030 0.015 0.027 0.014 0.033 0.016 
H ( 37) 0.022 0.012 0.019 0.010 0.026 0.014 
C ( 38) 0.000 0.004 0.001 0.003 0.001 0.006 
H ( 39) 0.001 0.001 0.003 0.000 0.004 0.002 
 
  
H ( 40) 0.010 0.004 0.008 0.003 0.011 0.005 
N ( 41) 0.005 0.008 0.003 0.006 0.006 0.009 
C ( 42) 0.007 0.004 0.006 0.004 0.008 0.005 
H ( 43) 0.018 0.009 0.017 0.009 0.019 0.010 
H ( 44) 0.007 0.003 0.006 0.003 0.008 0.004 
O ( 45) 0.048 0.045 0.042 0.039 0.054 0.051 
O ( 46) 0.048 0.045 0.042 0.039 0.054 0.050 
H ( 47) 0.015 0.013 0.015 0.013 0.014 0.013 
H ( 48) 0.015 0.013 0.015 0.013 0.015 0.013 
C ( 49) 0.001 0.000 0.002 0.000 0.001 0.001 
O ( 50) 0.007 0.007 0.006 0.007 0.007 0.008 
H ( 51) 0.008 0.003 0.009 0.003 0.008 0.003 
H ( 52) 0.006 0.002 0.006 0.002 0.007 0.003 
H ( 53) 0.007 0.005 0.006 0.005 0.007 0.006 
C ( 54) 0.002 0.002 0.002 0.002 0.001 0.002 
O ( 55) 0.006 0.007 0.005 0.007 0.006 0.007 
H ( 56) 0.001 0.001 0.001 0.001 0.001 0.001 
Molecular docking and binding energy calculations 
Mitoxantrone anticancer drug is known to do its anticancer activity via DNA intercalation, 
inhibition of transferase human CDK2 and inhibition of topoisomerase II [33-36]. 
Accordingly, we docked it into the crystal structures of protein kinase PknB and DNA 
employing intercalation interactions. The coordinates for the protein structure and DNA 
was obtained from the RCSB Protein Data Bank (PDB; 2FUM (Resolution: 2.89 Å) [37] 
and 1G3X, (Resolution: 2.7 Å) [38]. Protein Structures were prepared using Discovery 
Studio (DS 2.0) software package [39]. The invalid or missing residues were added and the 
structures were aligned using the protein structure alignment module. Hydrogen atoms 
were added and the structure was minimized using CHARMM force field to relax the 
backbone and to remove any clashes. Mitoxantrone was optimized by DFT method 
(B3LYB/6-31+G(d)) using G16 software. C-Docker with its default parameters was used 
to dock the MX into protein kinase PknB and DNA active sites. Fig. 4 shows binding model 
of mitoxantrone with protein kinase PknB transferase and DNA. The results are 
summarized in Table 2 along with our reported results of the structurally related AQ4, 
AQ4H and 1,4-DAAQ for comparison [40]. One can see that MX is more potent drug than 
other anthraquinone drugs. The interaction of MX with CDK2 (interaction energy, -
69.747) is stronger than AQ4, AQ4H and 1,4-DAAQ. For DNA intercalation binding MX 
is the most binder (interaction energy, -73.051) as can be seen from Table 2. 
Table 2. C-Docker interaction energy and binding energy of MX and AQ4, AQ4H and 
1,4-DAAQ with CDK2 enzyme and DNA 
  
System binding energy interaction energy 
MX/CDK2 -45.484 -69.747 
AQ4/CDK2 -38.880 -58.077 
AQ4H/CDK2 -33.340 -52.914 
1,4-DAAQ/CDK2 -20.632 -30.751 
MX/DNA (intercalation -62.847 -73.051 
AQ4/DNA (intercalation) -53.665 -54.189 
AQ4H/DNA (intercalation) -58.357 -57.331 
1,4-DAAQ/DNA (intercalation) -15.909 -26.080 
Docking of MX in CDK2 active site revealed the formation of two H-bonds. One between 
MX:O50 and GLY97:HN of distance 2.182 Å and DHA angle of 129.8o. The second, more 
stronger, H-bond between MX:O55 and residue LYS140 of distance 1.858 Å and DHA 
angle of 125.4o (Fig. 4). Docking of MX in DNA revealed the formation of two H-bonds. 
One between MX:H59 and Cytocine 621:O2 of distance 2.120 Å and DHA angle of 159.9o. 
The second, H-bond between MX:H60 and residue Thymine 619:O3 of distance 2.212 Å 
















Fig. 4. 3D nonbonding interactions of MX with ATP active site of CDK2 and DNA. 
a) showing the MX in the active site sphere of CDK2, b) hydrogen bonding interaction 
between MX and CDK2 active site, c) showing a focused view of hydrogen bonding 
interaction between MX and CDK2 active site, d) showing MX/DNA intercalation 
complex, d) and f) showing the hydrogen bonding interaction between MX and DNA 
bases. 
 
2.1.2. Charge-Transfer Complexes of MX: 
To understand the mechanism of interaction between MX and biological systems and to 
find out, particularly, the role of charge transfer forces in such interaction, we investigate 
the ability of MX to act as an electron acceptor with known charge transfer (CT) donors. 
For this study p-phenylenediamine (PDA) [43,44], pyrene, (PY) [45-49] and 
hexamethylbenzene, (HMB) [50-52] were selected as electron donors. Spectroscopic tools 
as UV-VIS absorption spectroscopy, fluorescence emission spectroscopy and NMR 
spectroscopy usually used to study CT complexes. Of which the oldest way is the UV-VIS 
absorption spectroscopy. Comparing to UV-VIS absorption spectroscopy and fluorescence 
emission spectroscopy, NMR tool is the most sensitive/accurate. NMR has been 
successfully used to evaluate equilibrium constants in hydrogen-bonding systems [53-55] 
and later in CT systems [56,57] since the two types of equilibria are formally the same. 
Further, NMR is extremely sensitive to small changes in the electronic environment of a 
magnetic nucleus, and a study of the appropriate NMR parameters may be another means 
of obtaining structural information about molecular complexes.  
1H NMR spectra for the complexes of Mitoxantrone with CT donors used were determined 
in CDCl3. 1H NMR spectra of different mixtures of PY and MX are represented in Figs. 5-
7. The protons of the acceptor (MX) in all complexes, are shifted upfield [58,59]. The 
experimental proton chemical shift differences between the complexed and the free MX 
were measured three times to minimize the experimental error. The uncertainty (standard 





Fig. 5. 1H NMR spectrum of H(2) of MX in its mixtures with PY; concentration of MX is 
6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 0.0512, 
0.0637, 0.0761, and 0.1016 M. 
 
  




Fig. 6. 1H NMR spectrum of H(6) of MX in its mixtures with PY; concentration of MX 
is 6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 
0.0512, 0.0637, 0.0761, and 0.1016 M.   




Fig. 7. 1H NMR spectrum of H(5) of MX in its mixtures with PY; concentration of MX 
is 6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 
0.0512, 0.0637, 0.0761, and 0.1016 M. 
   




Table 3 shows the maximum chemical shift differences of different protons of MX in their 
charge-transfer complexes with CT donors. Figure (6S), in the Supplementary Materials, 
shows how different acceptor-protons shifts are changed with the donor concentration in 
the system PDA/1,4-DAAQ. 
 
Table 3. Maximum upfield chemical shift differences (Hz) of different protonsa of MX in 
their mixtures with CT-donors and measured properties of their charge-transfer complexes. 
System H(2) H(3) H(5) H(6) H(7) H(8) D2, max. (Hz) 
K11 (M-1) D11 (Hz) 
PDA/MX -3.929 -3.929 -0.024 -0.854 -0.854 -0.024 -3.929 4.178±1.10 -14.31±4.45 
PY/MX -39.66 -39.66 -8.60 -12.04 -12.04 -8.60 -39.66 1.240±0.31 -326.42±80.21 
HMB/MX -12.08 -12.08 -4.18 -5.31 -5.31 -4.18 -12.08 2.527±0.68 -63.21±8.79 




Association Constant Determination 
NMR chemical shift data can be used for the determination of association constants of 
equilibria involving fast reactions could be applied to CT complex formation. There is a 
number of chemical-shift determinations from association constants for typical organic CT 
complexes have been made [57,60-66]. 
Protons equivalent to H(2)  were chosen for equilibrium constant determinations because 
it is a singlet band in MX and clear enough to follow. The equation below [28,29] is used 
to determine the association constant of the non-covalent complex formed. In the below 
equation, D is the chemical shift difference between that of HMB/MX mixture (H(2) 
nucleus) and the chemical shift of the same nucleus in the pure acceptor (MX). D11 is the 
difference of chemical shift between the pure complex and the pure acceptor (MX). [L] is 
the varied donor (HMB) concentration and K11 is the stability constant. A typical plot of 
1/D vs 1/L, for the system HMB/MX using this equation below is shown in Fig. (8). The 
shift in pure complex, D11, and the association constant, K11, were calculated from the 




The maximum observed shifts for H(2) in the acceptor, the determined association constant 
and the shifts of H(2) of the acceptor in the pure complex are given in Table (3). The 
observed chemical shift is a direct effect of molecular complexation. The major advantage 
of the NMR method compared with UV-VIS spectra is that complexes can be studied that 
have no separate CT band in the visible or ultraviolet spectrum, or where the CT band is 
buried beneath the spectrum of one of the components. The stability constant of the formed 
CT molecular complexes of MX with charge transfer donors are 4.178, 2.527 and 1.240 M-1 
for PDA/MX, HMB/MX and PY/MX respectively. These values are comparable with our 
previous reported results for anthraquinones with CT donors [28,29]. PDA/MX is the most 
stable complex reflecting the largest interaction between MX and the strongest donor PDA. 
 
The Chemical Shift of Pure Complex 
A consideration of the chemical shifts of pure complexes in Table (3) shows first, that all 
complex shifts are to higher field, and second, that larger shifts are associated with lower 
equilibrium constants. These results can be rationalized by a consideration of the possible 
effects on the acceptor proton resonance position that the donor might have.  These effects 
1 1 1
11 11 11D D D
= +
K L[ ]
are: 1. Transfer of charge from donor to acceptor, 2. Effect on acceptor protons of ring 
currents in the donor, 3.   Electric field effects of the donor on acceptor protons, 4. 
Modification of ring currents in acceptor, if present, by interaction with the donor, 5. 
Alteration of the paramagnetic contribution to the acceptor protons shifts. Effect 1 would 
result in an upfield shift if the electron density in the acceptor molecule were increased by 
transfer of charge from the donor. All theories of p- molecular complexes agree, however, 
that the amount of such charge transfer is very small.   Using the results of Fraenkel. et al., 
[67] which indicate that the shielding of a s-proton is increased by approximately   10 
p.p.m.  for a one p-electron increase on the adjacent carbon, one calculates that there would 
have to be a “transfer” of 0.14 electron from donor to acceptor to explain the maximum 
shift. Further, if effect 1 were the cause of the upfield shift, this shift should go to even 
higher fields as complexes become stronger.   Such is not the case, and therefore effect 1 
is ruled out.  
Effect 2 would also give an upfield shift. This effect is certainly of importance and may be 
the principal cause of the upfield shift of all complexes. The upfield shifts are 
approximately the same order as those discussed by Schneider [68].  
Effect 3 would be very small since the donor molecules have very small dipole moments. 
Effect 4 can be ruled out because, regardless of the way in which the acceptor ring currents 
were modified by interactions with the donor, the effect would be expected to increase as 
the complex became stronger. This effect, like effect 1, is unlikely to be important because 
complex formation is only a small perturbation on the ground state of the acceptor. Effect 
5 would predict a downfield shift of the acceptor protons.  A combination of this effect 
with effect 2 may be the explanation of the order and direction of the D11 values.  
In summary, this study has shown that NMR can be used to evaluate association constant 
for p-molecular complexes. In this respect, it can serve as a valuable supplement to the 
Benesi-Hildebrand method [69,70].  The shifts of acceptor protons in a pure complex, 
which are also obtained in these experiments, can be rationalized in terms of the effect of 
ring currents of the donor on the acceptor molecule and a new contribution to the 
paramagnetic part of the chemical shift. From this study, it is found that MX can act as a 
CT acceptor and form CT complexes with CT donors. This study also, confirms the 









Plot of 1/∆ vs 1/L for H(2) chemical shifts in HMB/MX charge transfer complex 
 
   
 
Numeration used to define tri-cyclic anthraquinone ring positions in MX. 
 
Fig. 8. NMR spectral data and atomic numeration of the ring in MX. 
  




























In this work, we investigated, computationally, the structures and energies of different intra 
molecular hydrogen bonding conformers of the anthraquinone anticancer drug 
mitoxantrone using DFT method. Five conformers within the energy range 0.000-48.495 
kcal/mol were investigated. From the calculation of the molecular reactivity descriptors 
and frontier molecular orbitals, HOMO and LUMO, we found that MX is more likely to 
act as an electophile than being as a nucleophile. This finding is also, confirmed by the 
NMR study of charge transfer complexes interaction that shows MX acts as an electron 
acceptor with known charge transfer donors. Docking results confirms the higher potency 
of MX compared with other anthraquinone anticancer drugs. Experimental NMR studies 
of the charge transfer molecular complexes of MX with CT donors prove the importance 
of the CT binding forces in the interaction of MX with biological molecules. Also, NMR 
studies of the charge transfer molecular complexes of MX with CT donors confirms the 
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Fig. 1. Optimized Structure of MX conformers showing atomic numeration, H-bonding and 
relative energy. 
 
Fig. 2. Calculated natural atomic charges of MX. 
 
Fig. 3. Important molecular orbitals surface with their energies and molecular electrostatic 
potential of MX. 
 
Fig. 4. 3D nonbonding interactions of MX with ATP active site of CDK2 and DNA. a) 
showing the MX in the active site sphere of CDK2, b) hydrogen bonding interaction between 
MX and CDK2 active site, c) showing a focused view of hydrogen bonding interaction 
between MX and CDK2 active site, d) showing MX/DNA intercalation complex, d) and f) 
showing the hydrogen bonding interaction between MX and DNA bases. 
 
Fig. 5. 1H NMR spectrum of H(2) of MX in its mixtures with PY; concentration of MX is 
6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 0.0512, 0.0637, 
0.0761, and 0.1016 M. 
 
Fig. 6. 1H NMR spectrum of H(6) of MX in its mixtures with PY; concentration of MX is 
6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 0.0512, 0.0637, 
0.0761, and 0.1016 M. 
 
Fig. 7. 1H NMR spectrum of H(5) of MX in its mixtures with PY; concentration of MX is 
6.031x10-3 M and concentrations of PY from bottom to top are: 0.0, 0.0250, 0.0512, 0.0637, 
0.0761, and 0.1016 M. 
 
Fig. 8. NMR spectral data and atomic numeration of the ring in MX. 
